GT Biopharma (NASDAQ:GTBP) Posts Earnings Results, Misses Estimates By $0.04 EPS

GT Biopharma (NASDAQ:GTBP) posted its quarterly earnings results on Friday, August 14th. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.04), Zacks reports.

GT Biopharma Stock Performance

GT Biopharma stock opened at $11.63 on Tuesday. GT Biopharma has a fifty-two week low of $4.91 and a fifty-two week high of $34.25. The firm has a market capitalization of $20.93 million, a price-to-earnings ratio of -0.08 and a beta of 0.91. The stock’s fifty day moving average is $8.01 and its two-hundred day moving average is $9.66.

Wall Street Analyst Weigh In

GTBP has been the topic of a number of research analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of GT Biopharma in a report on Wednesday, July 8th. Wall Street Zen cut shares of GT Biopharma to a “strong sell” rating in a report on Saturday. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has a consensus rating of “Sell”.

GT Biopharma Company Profile

GT Biopharma, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel immuno-oncology therapies utilizing its proprietary Tri-specific NK cell engager (TriKE) platform. This technology is designed to harness and enhance the body’s natural killer (NK) cells by simultaneously binding tumor antigens and interleukin-15 (IL-15), stimulating NK cell proliferation and targeted cytotoxicity. By focusing on NK cell engagement rather than T-cell activation, the company aims to offer therapies with potentially improved safety profiles and reduced immune-related adverse events.

The company’s lead candidate, GTB-3550, is currently in clinical trials for hematologic malignancies such as acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and myelodysplastic syndromes (MDS).